Immunotherapy of human cancer: lessons from mice [A Commentary]
It has always been difficult to translate mouse models into clinical therapies. The study of cancer immunity in mice has resulted in the identification of heat shock proteins as chaperones of antigenic peptides, and their possible use in the immunotherapy of human cancer. However, these immunotherapies also have to contend with an approval process designed for testing drugs. In a Commentary in the November 2000 issue of Nature Immunology (Vol. 1, No. 5), Pramod Srivastava of Farmington, Connecticut, USA, reflects on the challenges posed by immunotherapy, especially those unique to heat shock proteins, and suggests that different endpoints and objectives may need to be considered when evaluating the efficacy of newer approaches.
Pramod K. Srivastava
Center for Immunotherapy of Cancer and Infectious Diseases (MC1601)
University of Connecticut School of Medicine
Farmington, CT 06030-1601
Message posted by: Trevor M. D'Souza